Figure 6.

Plerixafor combination with dasatinib increases neurologic symptoms of leukemic mice. (A) Percentage incidence of neurologic symptoms in dasatinib only and combination group (i-ii) after excluding 5 mice from each group, which were taken off treatment at day 68. (B) Incidence of neurologic symptoms, from first occurrence of symptoms to death in symptomatic mice. Significant difference was observed between dasatinib only and dasatinib + plerixafor groups (P = .0002, log-rank test) in the occurrence of neurologic symptoms. (C) Hematoxylin and eosin (left panel) and anti-GFP immunohistochemistry (right panel) on brain sections. Arrow indicates the area of the brain, which is shown in higher magnification normal brain structure (i-vi) and leukemic infiltrates (vii-x).